Accession Number: | 0001209191-21-039572 |
Date: | 2021-06-08 |
Issuer: | SYROS PHARMACEUTICALS, INC. (SYRS) |
Original Submission Date: |
ALLES MARK J
C/O SYROS PHARMACEUTICALS, INC.
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 6.3 | 2021-06-08 | deemed execution date | A | 17,500 (a) | 2031-06-07 | common stock 17,500 | $6.30 | 17,500 | direct |
ID | footnote |
---|---|
f1 | the option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. |